SGLT2 inhibitor and fibrosis progression in MASLD: Correspondence to letter to the editor on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”
Clinical and Molecular Hepatology · 06.11.2026
DOI: 10.3350/cmh.2026.0363 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 06.11.2026. Verfasst von Jonggi Choi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. j.choi@amc.seoul.kr.
Themen: Diabetes mellitus
Abstract (Originalsprache)
commentary on our study.1,2 We appreciate their careful evaluation of several key methodological aspects, which represent important considerations for refining the interpretation of real-world observational data.In response, we performed additional analyses and provided further clarification to address these points.We conducted additional subgroup analyses stratifying patients according to normal alanine aminotransferase (ALT) thresholds (male
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. j.choi@amc.seoul.kr.
- Liver Center, Gastroenterology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. j.choi@amc.seoul.kr.
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. j.choi@amc.seoul.kr.
- Liver Center, Gastroenterology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Chung.Raymond@mgh.harvard.edu.
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Chung.Raymond@mgh.harvard.edu.
Zitieren
APA
Choi, J., & Chung, R. T. (2026). SGLT2 inhibitor and fibrosis progression in MASLD: Correspondence to letter to the editor on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0363
Vancouver
Choi J, Chung RT. SGLT2 inhibitor and fibrosis progression in MASLD: Correspondence to letter to the editor on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0363
BibTeX
@article{Choi2026,
author = {Choi, Jonggi and Chung, Raymond T},
title = {SGLT2 inhibitor and fibrosis progression in MASLD: Correspondence to letter to the editor on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2026.0363}
}
EUVIMED